Lanifibranor Completed Phase 2 Trials for Diffuse Systemic Sclerosis / Diffuse Cutaneous Systemic Sclerosis Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02503644Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis